Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies.

Dylgjeri E, McNair C, Goodwin JF, Raymon HK, McCue PA, Shafi AA, Leiby BE, de Leeuw R, Kothari V, McCann JJ, Mandigo AC, Chand SN, Schiewer MJ, Brand LJ, Vasilevskaya I, Gordon N, Laufer TS, Gomella LG, Lallas CD, Trabulsi EJ, Feng FY, Filvaroff EH, Hege K, Rathkopf D, Knudsen KE.

Clin Cancer Res. 2019 Jul 2. doi: 10.1158/1078-0432.CCR-18-2207. [Epub ahead of print]

PMID:
31266833
2.

DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway.

Kothari V, Goodwin JF, Zhao SG, Drake JM, Yin Y, Chang SL, Evans JR, Wilder-Romans K, Gabbara K, Dylgjeri E, Chou J, Sun G, Tomlins SA, Mehra R, Hege K, Filvaroff EH, Schaeffer EM, Karnes RJ, Quigley DA, Rathkopf DE, He HH, Speers C, Spratt DE, Gilbert LA, Ashworth A, Chinnaiyan AM, Raj GV, Knudsen KE, Feng FY.

Clin Cancer Res. 2019 Jul 2. doi: 10.1158/1078-0432.CCR-18-2387. [Epub ahead of print]

PMID:
31266829
3.

7OPhase I study of CC-90011 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL).

Hollebecque A, de Bono JS, Plummer R, Isambert N, Martin-Romano P, Baudin E, Mora S, Filvaroff E, Lamba M, Nikolova Z.

Ann Oncol. 2019 Feb 1;30(Supplement_1). pii: mdz029. doi: 10.1093/annonc/mdz029. No abstract available.

PMID:
30810203
4.

Efficacy of a Covalent ERK1/2 Inhibitor, CC-90003, in KRAS-Mutant Cancer Models Reveals Novel Mechanisms of Response and Resistance.

Aronchik I, Dai Y, Labenski M, Barnes C, Jones T, Qiao L, Beebe L, Malek M, Elis W, Shi T, Mavrommatis K, Bray GL, Filvaroff EH.

Mol Cancer Res. 2019 Feb;17(2):642-654. doi: 10.1158/1541-7786.MCR-17-0554. Epub 2018 Oct 1.

PMID:
30275173
5.

Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia.

Thijssen R, Ter Burg J, Garrick B, van Bochove GG, Brown JR, Fernandes SM, Rodríguez MS, Michot JM, Hallek M, Eichhorst B, Reinhardt HC, Bendell J, Derks IA, van Kampen RJ, Hege K, Kersten MJ, Trowe T, Filvaroff EH, Eldering E, Kater AP.

Blood. 2016 Jul 28;128(4):574-83. doi: 10.1182/blood-2016-02-700328. Epub 2016 May 27.

6.

MET Suppresses Epithelial VEGFR2 via Intracrine VEGF-induced Endoplasmic Reticulum-associated Degradation.

Chen TT, Filvaroff E, Peng J, Marsters S, Jubb A, Koeppen H, Merchant M, Ashkenazi A.

EBioMedicine. 2015 Mar 28;2(5):406-20. doi: 10.1016/j.ebiom.2015.03.021. eCollection 2015 May.

7.

A technology platform to assess multiple cancer agents simultaneously within a patient's tumor.

Klinghoffer RA, Bahrami SB, Hatton BA, Frazier JP, Moreno-Gonzalez A, Strand AD, Kerwin WS, Casalini JR, Thirstrup DJ, You S, Morris SM, Watts KL, Veiseh M, Grenley MO, Tretyak I, Dey J, Carleton M, Beirne E, Pedro KD, Ditzler SH, Girard EJ, Deckwerth TL, Bertout JA, Meleo KA, Filvaroff EH, Chopra R, Press OW, Olson JM.

Sci Transl Med. 2015 Apr 22;7(284):284ra58. doi: 10.1126/scitranslmed.aaa7489.

8.

Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit.

Koeppen H, Yu W, Zha J, Pandita A, Penuel E, Rangell L, Raja R, Mohan S, Patel R, Desai R, Fu L, Do A, Parab V, Xia X, Januario T, Louie SG, Filvaroff E, Shames DS, Wistuba I, Lipkind M, Huang J, Lazarov M, Ramakrishnan V, Amler L, Phan SC, Patel P, Peterson A, Yauch RL.

Clin Cancer Res. 2014 Sep 1;20(17):4488-98. doi: 10.1158/1078-0432.CCR-13-1836. Epub 2014 Mar 31.

9.

Nonclinical evaluation of the serum pharmacodynamic biomarkers HGF and shed MET following dosing with the anti-MET monovalent monoclonal antibody onartuzumab.

Mai E, Zheng Z, Chen Y, Peng J, Severin C, Filvaroff E, Romero M, Mallet W, Kaur S, Gelzleichter T, Nijem I, Merchant M, Young JC.

Mol Cancer Ther. 2014 Feb;13(2):540-52. doi: 10.1158/1535-7163.MCT-13-0494. Epub 2013 Nov 20.

10.

Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1.

Wu AL, Kolumam G, Stawicki S, Chen Y, Li J, Zavala-Solorio J, Phamluong K, Feng B, Li L, Marsters S, Kates L, van Bruggen N, Leabman M, Wong A, West D, Stern H, Luis E, Kim HS, Yansura D, Peterson AS, Filvaroff E, Wu Y, Sonoda J.

Sci Transl Med. 2011 Dec 14;3(113):113ra126. doi: 10.1126/scitranslmed.3002669.

11.

Viable tumor tissue detection in murine metastatic breast cancer by whole-body MRI and multispectral analysis.

Barck KH, Willis B, Ross J, French DM, Filvaroff EH, Carano RA.

Magn Reson Med. 2009 Dec;62(6):1423-30. doi: 10.1002/mrm.22109.

12.

Novel therapeutic targets along the Th17 pathway.

Ouyang W, Filvaroff E, Hu Y, Grogan J.

Eur J Immunol. 2009 Mar;39(3):670-5. doi: 10.1002/eji.200839105.

13.

Blocking neuropilin-2 function inhibits tumor cell metastasis.

Caunt M, Mak J, Liang WC, Stawicki S, Pan Q, Tong RK, Kowalski J, Ho C, Reslan HB, Ross J, Berry L, Kasman I, Zlot C, Cheng Z, Le Couter J, Filvaroff EH, Plowman G, Peale F, French D, Carano R, Koch AW, Wu Y, Watts RJ, Tessier-Lavigne M, Bagri A.

Cancer Cell. 2008 Apr;13(4):331-42. doi: 10.1016/j.ccr.2008.01.029.

14.

The role of Egfl7 in vascular morphogenesis.

Schmidt M, De Mazière A, Smyczek T, Gray A, Parker L, Filvaroff E, French D, van Dijk S, Klumperman J, Ye W.

Novartis Found Symp. 2007;283:18-28; discussion 28-36, 238-41.

PMID:
18300411
15.

TGF-beta regulates the mechanical properties and composition of bone matrix.

Balooch G, Balooch M, Nalla RK, Schilling S, Filvaroff EH, Marshall GW, Marshall SJ, Ritchie RO, Derynck R, Alliston T.

Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):18813-8. Epub 2005 Dec 14.

16.

TWEAK attenuates the transition from innate to adaptive immunity.

Maecker H, Varfolomeev E, Kischkel F, Lawrence D, LeBlanc H, Lee W, Hurst S, Danilenko D, Li J, Filvaroff E, Yang B, Daniel D, Ashkenazi A.

Cell. 2005 Dec 2;123(5):931-44.

17.

Loss of the serine/threonine kinase fused results in postnatal growth defects and lethality due to progressive hydrocephalus.

Merchant M, Evangelista M, Luoh SM, Frantz GD, Chalasani S, Carano RA, van Hoy M, Ramirez J, Ogasawara AK, McFarland LM, Filvaroff EH, French DM, de Sauvage FJ.

Mol Cell Biol. 2005 Aug;25(16):7054-68.

18.

Angiogenesis is required for successful bone induction during distraction osteogenesis.

Fang TD, Salim A, Xia W, Nacamuli RP, Guccione S, Song HM, Carano RA, Filvaroff EH, Bednarski MD, Giaccia AJ, Longaker MT.

J Bone Miner Res. 2005 Jul;20(7):1114-24. Epub 2005 Mar 7.

19.

VEGF and bone.

Filvaroff EH.

J Musculoskelet Neuronal Interact. 2003 Dec;3(4):304-7; discussion 320-1. No abstract available.

20.

Effect of anti-TGF-beta antibodies in syngeneic mouse models of metastasis.

Carano R, Li Y, Bao M, Li J, Berry L, Ross J, Kowalski J, French D, Dugger D, Schwall R, Wang Y, Fei D, Moseley SL, Filvaroff EH.

J Musculoskelet Neuronal Interact. 2004 Dec;4(4):377-8. No abstract available.

21.

WISP-1 is an osteoblastic regulator expressed during skeletal development and fracture repair.

French DM, Kaul RJ, D'Souza AL, Crowley CW, Bao M, Frantz GD, Filvaroff EH, Desnoyers L.

Am J Pathol. 2004 Sep;165(3):855-67.

22.

Creation and characterization of a mouse model of mandibular distraction osteogenesis.

Fang TD, Nacamuli RP, Song HM, Fong KD, Warren SM, Salim A, Carano RA, Filvaroff EH, Longaker MT.

Bone. 2004 Jun;34(6):1004-12.

PMID:
15193546
23.

Albumin stimulates the accumulation of extracellular matrix in renal tubular epithelial cells.

Stephan JP, Mao W, Filvaroff E, Cai L, Rabkin R, Pan G.

Am J Nephrol. 2004 Jan-Feb;24(1):14-9. Epub 2003 Dec 3.

PMID:
14654729
24.

Angiogenesis and bone repair.

Carano RA, Filvaroff EH.

Drug Discov Today. 2003 Nov 1;8(21):980-9. Review.

PMID:
14643161
25.

The effect of TGF-beta 2 on dentin apposition and hardness in transgenic mice.

DenBesten PK, Machule D, Gallagher R, Marshall GW Jr, Mathews C, Filvaroff E.

Adv Dent Res. 2001 Aug;15:39-41.

PMID:
12640737
26.

A slow release formulation of insulin as a treatment for osteoarthritis.

Cai L, Okumu FW, Cleland JL, Beresini M, Hogue D, Lin Z, Filvaroff EH.

Osteoarthritis Cartilage. 2002 Sep;10(9):692-706.

27.

Stanniocalcin 1 alters muscle and bone structure and function in transgenic mice.

Filvaroff EH, Guillet S, Zlot C, Bao M, Ingle G, Steinmetz H, Hoeffel J, Bunting S, Ross J, Carano RA, Powell-Braxton L, Wagner GF, Eckert R, Gerritsen ME, French DM.

Endocrinology. 2002 Sep;143(9):3681-90.

PMID:
12193584
28.

Interleukin 17 induced nitric oxide suppresses matrix synthesis and protects cartilage from matrix breakdown.

Cai L, Suboc P, Hogue DA, Fei DT, Filvaroff EH.

J Rheumatol. 2002 Aug;29(8):1725-36.

PMID:
12180737
29.

Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover.

Street J, Bao M, deGuzman L, Bunting S, Peale FV Jr, Ferrara N, Steinmetz H, Hoeffel J, Cleland JL, Daugherty A, van Bruggen N, Redmond HP, Carano RA, Filvaroff EH.

Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):9656-61. Epub 2002 Jul 12.

30.

Pathways by which interleukin 17 induces articular cartilage breakdown in vitro and in vivo.

Cai L, Yin JP, Starovasnik MA, Hogue DA, Hillan KJ, Mort JS, Filvaroff EH.

Cytokine. 2001 Oct 7;16(1):10-21.

PMID:
11669582
31.

IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding.

Hymowitz SG, Filvaroff EH, Yin JP, Lee J, Cai L, Risser P, Maruoka M, Mao W, Foster J, Kelley RF, Pan G, Gurney AL, de Vos AM, Starovasnik MA.

EMBO J. 2001 Oct 1;20(19):5332-41.

32.

IL-1H, an interleukin 1-related protein that binds IL-18 receptor/IL-1Rrp.

Pan G, Risser P, Mao W, Baldwin DT, Zhong AW, Filvaroff E, Yansura D, Lewis L, Eigenbrot C, Henzel WJ, Vandlen R.

Cytokine. 2001 Jan 7;13(1):1-7.

PMID:
11145836
33.

Binding protein-3-selective insulin-like growth factor I variants: engineering, biodistributions, and clearance.

Dubaquié Y, Mortensen DL, Intintoli A, Hogue DA, Nakamura G, Rancatore P, Lester P, Sadick MD, Filvaroff E, Fielder PJ, Lowman HB.

Endocrinology. 2001 Jan;142(1):165-73.

PMID:
11145579
34.

Functional inactivation of the IGF-I receptor delays differentiation of skeletal muscle cells.

Cheng ZQ, Adi S, Wu NY, Hsiao D, Woo EJ, Filvaroff EH, Gustafson TA, Rosenthal SM.

J Endocrinol. 2000 Oct;167(1):175-82.

PMID:
11018765
35.

Inhibition of TGF-beta receptor signaling in osteoblasts leads to decreased bone remodeling and increased trabecular bone mass.

Filvaroff E, Erlebacher A, Ye J, Gitelman SE, Lotz J, Heillman M, Derynck R.

Development. 1999 Oct;126(19):4267-79.

36.

Bone remodelling: a signalling system for osteoclast regulation.

Filvaroff E, Derynck R.

Curr Biol. 1998 Sep 24;8(19):R679-82. Review.

37.

Osteoblastic responses to TGF-beta during bone remodeling.

Erlebacher A, Filvaroff EH, Ye JQ, Derynck R.

Mol Biol Cell. 1998 Jul;9(7):1903-18.

38.

Expression of a truncated, kinase-defective TGF-beta type II receptor in mouse skeletal tissue promotes terminal chondrocyte differentiation and osteoarthritis.

Serra R, Johnson M, Filvaroff EH, LaBorde J, Sheehan DM, Derynck R, Moses HL.

J Cell Biol. 1997 Oct 20;139(2):541-52.

39.
41.

Vgr-1/BMP-6 induces osteoblastic differentiation of pluripotential mesenchymal cells.

Gitelman SE, Kirk M, Ye JQ, Filvaroff EH, Kahn AJ, Derynck R.

Cell Growth Differ. 1995 Jul;6(7):827-36.

42.

Toward a molecular understanding of skeletal development.

Erlebacher A, Filvaroff EH, Gitelman SE, Derynck R.

Cell. 1995 Feb 10;80(3):371-8. Review. No abstract available.

44.

Bioengineered soluble HLA-B7. Genesis, characterization, and occurrence of dimerization.

Hiraki DD, See-Tho K, Filvaroff E, Krishnaswamy S, de Bello W, Taidi-Laskowski B, Grumet FC.

Hum Immunol. 1994 Jul;40(3):235-46.

PMID:
7960968
45.

Soluble form of an HLA-B7 class I antigen specifically suppresses humoral alloimmunization.

Grumet FC, Krishnaswamy S, See-Tho K, Filvaroff E, Hiraki DD.

Hum Immunol. 1994 Jul;40(3):228-34.

PMID:
7960967
46.
47.

An emerging complexity of receptors for transforming growth factor-beta.

Derynck R, Chen RH, Ebner R, Filvaroff EH, Lawler S.

Princess Takamatsu Symp. 1994;24:264-75. Review.

PMID:
8983081
48.
49.

Supplemental Content

Loading ...
Support Center